DDInter778 DDInter899
Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Fosaprepitant {u} (Compound) resembles {v} (Compound) Aprepitant
Fosaprepitant {u} (Compound) binds {v} (Gene) TACR1
Fosaprepitant {u} (Compound) is included by {v} (Pharmacologic Class) Neurokinin 1 Antagonists
Fosaprepitant {u} (Compound) causes {v} (Side Effect) Type I hypersensitivity
Fosaprepitant {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Fosaprepitant {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Fosaprepitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobicistat
Fosaprepitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Miconazole
Fosaprepitant {u} may lead to a major life threatening interaction when taken with {v} Entrectinib
Fosaprepitant {u} may lead to a major life threatening interaction when taken with {v} Terfenadine
Fosaprepitant (Compound) resembles Aprepitant (Compound)
Fosaprepitant (Compound) binds TACR1 (Gene)
Fosaprepitant (Compound) is included by Neurokinin 1 Antagonists (Pharmacologic Class)
Fosaprepitant (Compound) causes Type I hypersensitivity (Side Effect)
Fosaprepitant may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Fosaprepitant may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Fosaprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Fosaprepitant may cause a moderate interaction that could exacerbate diseases when taken with Miconazole
Fosaprepitant may lead to a major life threatening interaction when taken with Entrectinib
Fosaprepitant may lead to a major life threatening interaction when taken with Terfenadine